Reliable Quality

Affordable Innovation

Research Progress

Up to date, in addition to one product launched commercially and two products under New Drug Application (NDA) review, Henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide. 漢利康®( HLX01, rituximab injection), the first product of Henlius, has been granted approval by the National Medical Products Administration (NMPA) in February 2019 as the first China's biosimilar. The NDAs of HLX03 (adalimumab injection)and HLX02 (trastuzumab for injection) were accepted by the NMPA and assigned to priority review list. HLX02 is the first China-manufactured biosimilar to conduct a global, multi-centre Phase 3 clinical trial in Mainland China, Poland, Ukraine and the Philippines. Its Marketing Authorisation Application (MAA) was also accepted by European Medicines Agency(EMA)for review in June 2019. In May 2020, the Committee for Medical Products for Human Use (CHMP) of EMA adopted a positive opinion on MAA for HLX02.

Products in R&D
Generic Name
Study Phase
Potential Indication
Study Phase
Product Pipeline

With our efficient and innovative in-house capabilities, we have developed a diversified and advanced drug pipeline with a focus in the fields of oncology, autoimmune diseases etc. 


hg320挂赚钱宝网络卡 2019全年精准特马诗 pk10手机免费计划软件 福彩排列七玩法说明 股票软件下载大全 青海快3豹子号规律 安徽11选五前三走势图 中国彩吧论坛 湖北快3三形态走势图一 正规彩票投注app 上海体彩大乐透11选五 股票资配公司 股票行情大盘走势 安徽11选5开奖结果 新疆11选5遗漏号码查询 河南快3预测号码推荐 四川快乐12助手官方软件下载